ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

The prize honored discoveries that defined peripheral immune tolerance through regulatory T cells (Tregs) and the FOXP3 gene, ...

FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...

With the advent of commercial spaceflight, an increasing number of people may be heading into space in the coming years. Some ...

Pregnancy and breastfeeding induces the accumulation of specialized immune cells that reduce the chances of breast cancer ...

Scientists have found a way to transform hard-to-treat tumors into targets for the immune system. Using two protein stimulators, they activated strong T-cell and B-cell responses and built immune ...

Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...

A review of recent literature shows bioengineering is reshaping oncology, from synthetic biology to nanomedicine, but what's ...

Biosecurity has emerged as a critical consideration in the industrial biotechnology landscape, particularly as advances in artificial intelligence (AI), ...